Engineered small metal-binding protein tag improves the production of recombinant human growth hormone in the periplasm of *Escherichia coli*

David A. Perez-Perez¹, Elizeth Pioquinto-Avila¹, Eder Arredondo-Espinoza¹, Jose Ruben Morones-Ramirez¹,², Isaias Balderas-Renteria¹,² and Xristo Zarate¹,²

¹ Universidad Autonoma de Nuevo Leon, Facultad de Ciencias Quimicas, San Nicolas de los Garza, Mexico
² Universidad Autonoma de Nuevo Leon, Facultad de Ciencias Quimicas, Centro de Investigacion en Biotecnologia y Nanotecnologia, Parque de Investigacion e Innovacion Tecnologica, Apodaca, Mexico

Keywords
*Escherichia coli*; human growth hormone; PelB-SmbP; periplasm; protein expression and purification; SmbP

Correspondence
X. Zarate, Facultad de Ciencias Quimicas, Universidad Autonoma de Nuevo Leon, San Nicolas de los Garza, NL 66455, Mexico
Tel: +52 81 83294000 ext. 3444
E-mail: xristo.zaratekl@uanl.edu.mx

(Received 23 August 2019, revised 30 January 2020, accepted 10 February 2020)
doi:10.1002/2211-5463.12808

Fusion proteins play an important role in the production of recombinant proteins in *Escherichia coli*. They are mostly used for cytoplasmic expression since they can be designed to increase the solubility of the target protein, which then can be easily purified via affinity chromatography. In contrast, fusion proteins are not usually included in construct designs for periplasmic production. Instead, a signal sequence is inserted for protein transport into the periplasm and a C-terminal his-tag added for subsequent purification. Our research group has proposed the small metal-binding protein (SmbP) isolated from the periplasm of *Nitrosomonas europaea* as a new fusion protein to express recombinant proteins in the cytoplasm or periplasm of *E. coli*. SmbP also allows purification via immobilized metal affinity chromatography using Ni(II) ions. Recently, we have optimized the periplasmic production of proteins tagged with SmbP by exchanging its native signal peptide with one taken from pectate lyase B (PelB), substantially increasing the amount of protein produced. In this work, we have expressed and purified soluble bioactive human growth hormone (hGH) tagged with PelB-SmbP and obtained the highest periplasmic production reported for this protein so far. Its activity, tested on Nb2-11 cells, was equivalent to commercial growth hormone at 50 ng·mL⁻¹. Therefore, we strongly recommend the use of PelB-SmbP as a protein tag for the expression and purification of hGH or other possible target proteins in the periplasm of *E. coli*.

Many biopharmaceuticals are currently produced recombinantly in different microorganisms [1]. *Escherichia coli* is preferred because it can produce large quantities at low cost [2]. Unfortunately, *E. coli* has significant disadvantages as a host organism since it cannot carry out certain post-translational modifications, and often, the protein of interest can form inclusion bodies. Fusion proteins have helped greatly to deal with this problem since they can be designed to function as solubility tags, and some also allow purification via affinity chromatography [3]. Recombinant proteins produced in *E. coli* can be accumulated in the cytoplasm or periplasm [4]; usually, the cytoplasm is the first choice due to its higher protein production, but a drawback can be that it lacks the proper environment to facilitate disulfide bond formation. Within the periplasm, the Dsb protein family assists with proper folding for these proteins [5]. Periplasmic

Abbreviations
dNTP, deoxynucleotide triphosphate; hGH, human growth hormone; IMAC, immobilized metal affinity chromatography; LB, Luria–Bertani broth; OD₆₀₀, optical density at 600 nm; PelB, pectate lyase B; SmbP, small metal-binding protein; Tris, Tris(hydroxymethyl)-aminomethane.
expression offers additional advantages; for example, it contains much lower amounts of proteins and nucleic acids that can interfere with the purification process, and the periplasmic fraction can be easily obtained via an osmotic shock [6,7].

Recently, we have proposed two new fusion proteins: SmbP from Nitrosomonas europaea and CusF from E. coli [8–10]. The biology of both proteins involves the removal of metal ions from the bacteria, SmbP binding Ni(II), Cu(II), Zn(II), and Fe(III) ions [11], whereas CusF can bind Cu(I), Ag(I), and Cu(II) [9]. Both proteins are naturally found in the cell periplasm, and they contain a signal peptide dependent on the Sec pathway for transport to this location. Experiments in our laboratory have shown that SmbP and CusF function as solubility tags and can be purified employing IMAC, obtaining high purity, and very importantly, excellent final yields since these proteins have a molecular weight of only 10 kDa. We have made improvements to both proteins to increase protein quantity and purity [12,13]. In the case of SmbP, its signal peptide was exchanged for three different sequences: the signal peptides from the proteins CusF, PelB (Erwinia carotovora), and TorA (E. coli). The first two signal transport to occur via the Sec route and the third via the Tat route. Using any of the three different signal peptides, the periplasmic expression of fluorescent proteins marked with SmbP increased more than a 1000-fold, PelB-SmbP being slightly better than CusF-SmbP. As for TorA-SmbP, it transported folded proteins to the cell periplasm with a little less efficiency; although protein production with any of the different signal sequences is target protein-dependent [13].

The human growth hormone (hGH) is a protein produced, stored, and secreted by the anterior pituitary gland. It maintains positive nitrogen balance and initiates protein synthesis in muscle cells, raises amino acid uptake into skeletal muscle, regulates longitudinal bone growth, and protects cardiac myocytes and lymphoid cells against apoptosis [14]. Due to its variety of biological roles, hGH has been approved for the treatment of the following conditions: GH deficiency, idiopathic short stature, chronic kidney disease, Turner syndrome, Prader–Willi syndrome, SHOX gene haploinsufficiency, Noonan syndrome, and small for gestational age infants [15]. The incidence in children with hGH deficiency has been estimated to be about 1 in 4000 [16].

Mature hGH consists of 191 amino acid residues, with four cysteines being involved in two disulfide bonds [17]. Therefore, this protein is appropriate for expression in the periplasm of E. coli and for tagging with PelB-SmbP. In this work, we describe the expression and purification of recombinant hGH tagged with PelB-SmbP. Purification was carried out with an osmotic shock followed by metal affinity chromatography, and finally, the SmbP tag was removed with enterokinase. Pure hGH was assayed on the Nb2-11 cell line showing activity similar to that of commercial serotropin as positive control.

Materials and methods

DNA constructs

The pET30a vector containing the PelB-SmbP sequence (cloned using the NdeI and KpnI restriction sites) [13] was digested with NcoI and XhoI. The DNA sequence for hGH was optimized for E. coli expression and synthesized by GenScript (Piscataway, NJ, USA). After digestion with the same enzymes, it was ligated into pET30a-PelB-SmbP. The construct contains an enterokinase recognition sequence for tag removal, located between the fusion protein and hGH. E. coli strain DH5α was used for general cloning procedures and DNA maintenance. All constructs used in this work were fully characterized by sequencing.

Protein expression

The expression plasmid pET30a-PelB-SmbP-hGH was transformed into E. coli BL21(DE3) cells. For small-scale expression experiments, a single colony was used to inoculate LB broth–kanamycin (30 µg·mL⁻¹) and incubated at 37 °C. Once the OD₆₀₀ reached 0.4–0.6, protein expression was induced by the addition of 1 mM IPTG to a final concentration of 0.1 mM. The culture was incubated for 16 h at 25 °C. For 1-L expression, overnight cultures were used to inoculate LB-kanamycin in baffled flasks and incubated at 37 °C until OD₆₀₀ reached 0.4–0.6. IPTG was added to a final concentration of 0.1 mM, and again, the culture was incubated for 16 h at 25 °C.

Protein purification

Cells from the 1-L culture were harvested by centrifugation at 4 °C, and SmbP-hGH was extracted from the periplasm by osmotic shock [13]. The cells were resuspended in a hypertonic solution (200 mM Tris/HCl, 20% sucrose, 2 mM EDTA, 0.5 mg·mL⁻¹ lysozyme, pH 8.0) and incubated for 1 h at 4 °C. Cells were centrifuged at 24 500 g for 10 min and the supernatant collected. The remaining pellet was resuspended in water and incubated for 1 h at 4 °C followed by centrifugation at 24 500 g for 10 min at 4 °C. The supernatant from the hypotonic solution was combined with the supernatant from the hypertonic solution and dialyzed against buffer A (50 mM Tris/HCl, 500 mM NaCl, pH 8.0) at 4 °C. After dialysis, the supernatant was clarified by
centrifugation at 24,500 \(g\) for 10 min. Purification was performed using the AKTA Prime Plus FPLC (GE Healthcare, Chicago, IL, USA). The protein solution was loaded into a 5 mL HisTrap FF previously charged with Ni(II) and equilibrated with buffer A. The column was washed with buffer A until no more absorption at 254 nm was observed. hGH was eluted with an imidazole gradient (up to 200 mM) in 40 column volumes. All eluted fractions were analyzed by SDS/PAGE; the purity of hGH was calculated by densitometry using the software IMAGEJ (http://imagej.nih.gov/ij). Protein content was quantified by the Bradford reagent using BSA as the standard. One milligram of SmbP-hGH was digested with 50 units of enterokinase light chain (New England Biolabs, Ipswich, MA, USA) in a 2 mL reaction volume for 16 h at room temperature. After cleavage, the protein solution was dialyzed against 700 mL of buffer A for 1 h (this step was performed three times, the last for 16 h) and incubated with Profinity IMAC resin (Bio-Rad Laboratories, Hercules, CA, USA) charged with Ni(II) for 1 h. The resin was then centrifuged at 1500 \(g\) for 30 s, and the supernatant was collected and analyzed by SDS/PAGE as our final product.

**In vitro cell proliferation assay**

The biological activity of hGH was tested using Nb2-11 cells. The cells were cultured in suspension in Fischer’s medium supplemented with 10% fetal bovine serum, 10% horse serum, 0.075% sodium bicarbonate, 0.05 mM β-mercaptoethanol, and 2 mM glutamine at 37°C in a humidified atmosphere containing 5% CO₂. The cells were harvested by centrifugation and resuspended in the same medium without fetal bovine serum for 24 h to slow the rate of cell division. For the activity assay, approximately \(2 \times 10^6\) cells were seeded into a 96-well microtiter plate containing 100 \(\mu\)L of assay medium. Proliferation was promoted by adding different amounts of our purified hGH or a commercial product (serotropin from PiSA Pharmaceuticals, Guadalajara, JC, Mexico) over a concentration range of 3–50 ng/mL⁻¹. Cell growth was evaluated using the WST-1 assay [18], after 24 h of incubation with hGH.

**Statistical analysis**

The statistical analysis was done using GRAPHPAD PRISM version 5.0 (San Diego, CA, USA). Experiments were performed in triplicate. One-way ANOVA was used for multiple group comparisons (*\(P < 0.05\)). Tukey’s test was used to calculate statistical significance.

**Results and Discussion**

In order to first verify whether SmbP-hGH was being produced in the periplasm, we performed small-scale expression experiments followed by an osmotic shock. Figure 1 shows the SDS/PAGE analysis of the hypertonic and hypotonic fractions. A protein band, corresponding to the expected position of SmbP-hGH (approximately 32 kDa), was observed only in the hypotonic fractions. Previous experiments performed in our laboratory showed that red fluorescent protein tagged with PelB-SmbP was mostly present in that same fraction [13]. Interestingly, when the process was upscaled to a larger volume, some SmbP-hGH was also observed in the hypertonic fraction. For this reason, both fractions were pooled and dialyzed for protein purification. Figure S1 shows the SDS/PAGE analysis from the IMAC purification and all elution
fractions. After affinity chromatography, reaction with enterokinase, and a second chromatographic step to remove the SmbP tag, 98% pure recombinant hGH was obtained, a single band with a molecular mass of 22 kDa (Fig. 2). Therefore, the total quantity of hGH present in one liter of cell culture is 15.5 mg. Table 1 shows the full summary purification table [19], including percentage yields.

Different methodologies have been used to produce hGH in E. coli. Some of these include working with inclusion bodies and three or more purification steps, resulting in low yields or high costs [20]. One report for the production of hGH in the periplasm of E. coli showed a yield of 1.4 mg L\(^{-1}\) of culture of purified hGH, using PelB as a signal peptide and a C-terminal his-tag [21]. Our work clearly indicates that SmbP vastly improved hGH expression (10-fold), as compared with the his-tag alone.

In terms of the bioactivity of the recombinant hGH, Fig. 3 shows the results of a cell proliferation assay using the Nb2-11 cell line. This line derives from a transplanatable lymphoma from the lymph nodes of a male rat of the Noble strain. Following prolonged estrogen treatment, cellular proliferation is dependent on mammalian lactogens. This feature allows this cell line to be used in the determination of the biological activity of hGH [22]. Cells in the assay medium were treated with purified or commercial hGH, and BSA (as a negative control). Both hGH proteins show the ability to induce cell proliferation in a dose-dependent manner up to 50 ng mL\(^{-1}\), as previously reported [17,23]; no cell proliferation was observed with BSA. These results demonstrate that hGH tagged with PelB-SmbP and purified with our methodology has biological activity.

### Conclusions

We report for the first time the use of SmbP for the production of a biopharmaceutical product, describing an efficient and straightforward strategy for the production of hGH tagged with PelB-SmbP in the periplasm of E. coli. After the cleavage of SmbP, we have been able to produce 15.5 mg of active hGH at 98% purity per liter of culture. This technique could be useful for the production of other therapeutic proteins.

### Acknowledgements

We thank Mexico’s Consejo Nacional de Ciencia y Tecnología (CONACYT) for the financial support provided to DAPP and EPA during their graduate studies. This work was funded by Grants UANL-PAICYT CN567-15 and UANL-PAICYT CN942-19 awarded to XZ. We thank CHRISTUS-LATAM HUB CENTER OF EXCELLENCE AND INNOVATION, S.C. for supporting the open access article publication charge.

### Conflict of interest

The authors declare no conflict of interest.

### Author contributions

DAP-P made the DNA constructs, expressed and purified the recombinant human growth hormone,
performed cell culture assays, and wrote the manuscript. EP-A and EA-E performed cell culture assays. JRM-R and IB-R assisted with data interpretation and edited the manuscript. XZ designed the experiments, edited the manuscript, and proposed the research as principal investigator. All authors read and approved the final manuscript.

References

1 Overton TW (2014) Recombinant protein production in bacterial hosts. Drug Discov Today 19, 590–601.
2 Jozala AF, Geraldes DC, Tundisi LL, Feitosa VA, Breyer CA, Cardoso SL, Mazzola PG, de Oliveira-Nascimento L, Rangel-Yagui CO, Magalhães PO et al. (2016) Biopharmaceuticals from microorganisms: from production to purification. Braz J Microbiol 47, 51–63.
3 Young CL, Britton ZT and Robinson AS (2012) Recombinant protein expression and purification: a comprehensive review of affinity tags and microbial applications. Biotechnol J 7, 620–634.
4 Terpe K (2006) Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol 72, 211–222.
5 Ke N and Berkmen M (2014) Production of disulfide-bonded proteins in Escherichia coli. Curr Protoc Mol Biol 2014, 16.1B.21.
6 Dow BA, Tatulian SA and Davidson VL (2015) Use of the amicyanin signal sequence for efficient periplasmic expression in E. coli of a human antibody light chain variable domain. Protein Expr Purif 108, 9–12.
7 Ramanan RN, Tan JS, Mohamed MS, Ling TC, Tey BT and Ariff AB (2010) Optimization of osmotic shock process variables for enhancement of the release of periplasmic interferon-α2b from Escherichia coli using response surface method. Process Biochem 45, 196–202.
8 Vargas-Cortez T, Morones-Ramirez JR, Balderas-Renteria I and Zarate X (2016) Expression and purification of recombinant proteins in Escherichia coli tagged with a small metal-binding protein from Nitrosomonas europaea. Biochemistry 43, 11206–11213.
9 Vargas-Cortez T, Morones-Ramirez JR, Balderas-Renteria I and Zarate X (2017) Production of recombinant proteins in Escherichia coli tagged with the fusion protein CusF3H+. Protein Expr Purif 132, 44–49.
10 Santos BD, Morones-Ramirez JR, Balderas-Renteria I, Casillas-Vega NG, Galbraith DW and Zarate X (2019) Optimizing periplasmic expression in Escherichia coli for the production of recombinant proteins tagged with the small metal-binding protein SmbP. Mol Biotechnol 61, 451–460.
11 Blizzard RM (2012) History of growth hormone therapy. Indian J Pediatr 79, 87–91.
12 Ackland FM, Jones J, Buckler JMH, Dunger DB, Rayner PHW and Preece MA (1990) Growth hormone treatment in non-growth hormone-deficient children: effects of stopping treatment. Acta Paediatr Scand Suppl 79, 32–37.
13 Hoybye C, Cohen P, Hoffman AR, Ross R, Biller BMK and Christiansen JS (2015) Status of long-acting-growth hormone preparations – 2015. Growth Horm IGF Res 25, 201–206.
14 Tevarski Z, Šoltýsová A, Krahulec J, Stuchlík S and Tuřňa J (2014) High-level expression and purification of recombinant human growth hormone produced in soluble form in Escherichia coli. Protein Expr Purif 100, 40–47.
15 Berridge MV, Herst PM and Tan AS (2005) Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11, 127–152.
16 Burgess RR (2009) Chapter 4 Preparing a purification summary table. In Methods in Enzymology. Guide to Protein Purification, (Burgess RR and Deutscher MP, eds), 2nd edn, Vol. 463, pp. 29–34. Academic Press, Cambridge, MA.
17 Kim MJ, Park HS, Seo KH, Yang HJ, Kim SK and Choi JH (2013) Complete solubilization and purification of recombinant human growth hormone produced in Escherichia coli. PLoS ONE 8, e56168.
18 Sockolosky JT and Szoka FC (2013) Periplasmic production via the pET expression system of soluble, bioactive human growth hormone. Protein Expr Purif 87, 129–135.
19 Tanaka T, Shiu RPC, Gout PW, Beer CT, Noble RL and Friesen HG (1980) A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum. J Clin Endocrinol Metab 51, 1058–1063.
20 Nguyen MT, Koo BK, Thi Vu TT, Song JA, Chong SH, Jeong B, Ryu HB, Moh SH and Choe H (2014) Prokaryotic soluble overexpression and purification of bioactive human growth hormone by fusion to thioredoxin, maltose binding protein, and protein disulfide isomerase. PLoS ONE 9, 3–12.
**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig. S1.** 12% SDS/PAGE analysis of SmbP_hGH after first IMAC purification. Lane 1: protein marker; Lane 2: periplasmic hypotonic fraction; Lane 3: periplasmic hypotonic fraction; Lane 4: flow-through; Lane 5-51 elution fractions.

**Fig. S2.** Cell proliferation assay of purified hGH in the Nb2-11 cell line. Nb2-11 cells were exposure to 50 ng/ml of purified hGH, commercial hGH, and bovine serum albumin as a control. Here, polyhistidine tagged enterokinase was used to cleave SmbP from hGH, thus, after second IMAC purification, the enterokinase enzyme was completely removed.

**Table S1.** Statistical analysis of the cell proliferation assay. Turkey’s test was used to calculate statistical significance. One-way ANOVA was used for multiple group comparisons (*p < 0.05).